Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

The purpose of this study was to investigate the prognostic value of time to relapse in 188 adult patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) included on the Parma trial at the time of their first relapse. The median follow-up of these patients is 102 months after reg...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 1998-10, Vol.16 (10), p.3264-3269
Hauptverfasser:	GUGLIELMI, C, GOMEZ, F, SONNEVELD, P, GISSELBRECHT, C, VAN DER LELIE, H, CHAUVIN, F, PHILIP, T, HAGENBEEK, A, MARTELLI, M, SEBBAN, C, MILPIED, N, BRON, D, CAHN, J.-Y, SOMERS, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Marrow Transplantation Cisplatin - administration & dosage Combined Modality Therapy Cytarabine - administration & dosage Female Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - radiotherapy Lymphoma, Non-Hodgkin - therapy Male Medical sciences Middle Aged Prognosis Proportional Hazards Models Prospective Studies Recurrence Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!